AbbVie's Allergan Aesthetics announced that the FDA has accepted for review its supplemental Biologics License Application (sBLA) for BOTOX Cosmetic for masseter muscle prominence. If approved, this would be the first neurotoxin indicated for this condition in the U.S., expanding BOTOX Cosmetic's aesthetic indications.
AbbVie's Allergan Aesthetics has received FDA acceptance for review of an sBLA for BOTOX Cosmetic to treat masseter muscle prominence. This is a significant step towards potentially expanding the market for one of AbbVie's flagship products. If approved, BOTOX Cosmetic would be the first and only neurotoxin indicated for this condition in the U.S., opening up a new revenue stream and solidifying its leadership in the aesthetic market. This news is a positive catalyst for ABBV in the short to medium term, as it signals potential for increased sales and market share. The key opportunity for traders is the potential for increased BOTOX sales, while the risk lies in the possibility of the sBLA not being approved, though acceptance for review is a positive indicator.